GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » Valuation Rank

Myrexis (Myrexis) Valuation Rank


View and export this data going back to 2013. Start your Free Trial

What is Myrexis Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Myrexis Valuation Rank Related Terms

Thank you for viewing the detailed overview of Myrexis's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Myrexis (Myrexis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » Valuation Rank
Comparable Companies
TSXV:AUS.H TSXV:SIQ MGHL TSXV:LX.H NTWN OSTO:ITAL SDB NSE:AVSL RDGA LSE:BASK AASP CLOW BOM:531752 ARRT DKGH POYN BOM:540394 TSXV:PED.H BOM:538875 SPUP BOM:523558
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020
Website
http://www.myrexis.com
Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.
Executives
Xstelos Corp. 10 percent owner 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe director 1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper director 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman director, officer: Chairman, President and CEO 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle director 320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska director, officer: Chief Operating Officer 749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer director, officer: President and CEO C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden director, officer: President and CEO 320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie officer: Chief Operating Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108